文献速递临床试验与 GCP

营养不良结直肠癌手术患者术前免疫营养的疗效:多中心随机临床试验研究方案

Efficacy of preoperative immunonutrition in malnourished patients undergoing colorectal cancer surgery: a study protocol for a multicenter randomized clinical trial.
PubMed 文献 · Trials · 2025-09-29

本研究为多中心、平行、优效性随机临床试验,纳入NRS 2002评分3-5分的原发性结直肠癌患者176例(每组88例),随机接受术前7天口服免疫营养补充剂(400 mL/天,含精氨酸和ω-3脂肪酸)或单纯标准术前饮食,主要终点为术后30天内感染性并发症发生率。

要点

  • 纳入NRS 2002评分3-5分的原发性结直肠癌手术患者,随机1:1分组。
  • 干预组术前7天口服含精氨酸和ω-3脂肪酸的免疫营养补充剂400 mL/天。
  • 主要终点为术后30天内感染性并发症发生率,样本量176例(每组88例)。

核心结论

  • 研究旨在评估术前免疫营养对营养不良结直肠癌手术患者术后并发症的疗效。
  • 若术前免疫营养有效减少术后并发症,可支持针对营养不良结直肠癌患者的靶向营养干预策略。

研究设计与样本

  • 多中心、平行、优效性随机临床试验,纳入八家参与机构的原发性结直肠癌且NRS 2002评分3-5分的患者。
  • 计划样本量176例(每组88例),随机1:1分配至干预组或对照组。

主要发现

  • 样本量按感染性并发症发生率从对照组30%降至干预组12%计算,检验效能80%,双侧α=0.05。
  • 主要终点为术后30天内感染性并发症发生率。
  • 次要终点包括术后总体并发症发生率、住院时间、围术期体重变化及营养和免疫反应标志物变化。

关键数值与推荐

  • 干预组:术前7天口服免疫营养补充剂400 mL/天,含精氨酸和ω-3脂肪酸。
  • 对照组:单纯标准术前饮食。
  • 营养和免疫反应标志物包括血清转铁蛋白、前白蛋白、白蛋白、细胞因子、前列腺素E2、高敏C反应蛋白。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malnutrition is a significant risk factor for postoperative complications in patients undergoing colorectal cancer surgery. Although current guidelines recommend preoperative immunonutrition for malnourished patients, its clinical benefit remains controversial. Our previous randomized clinical trial assessing immunonutrition in unselected colon cancer patients showed no reduction in infectious complications. This study aims to evaluate the efficacy of preoperative immunonutrition in reducing postoperative complications in malnourished patients undergoing colorectal cancer surgery. METHODS: This multicenter, parallel, superiority, randomized clinical trial will include patients with primary colorectal cancer and Nutritional Risk Screening (NRS) 2002 score of 3-5 from eight participating institutions. Patients will be randomly assigned (1:1) to receive either preoperative immunonutrition with oral nutritional supplements (400 mL/day) containing arginine and ω-3 fatty acids for 7 days before surgery (intervention group) or a standard preoperative diet alone (control group). The primary endpoint is the rate of infectious complications within 30 days postoperatively. Secondary endpoints include overall postoperative complication rate, length of hospital stay, perioperative body weight changes, and alterations in nutritional and immune response markers (serum transferrin, prealbumin, albumin, cytokines, prostaglandin E2, high-sensitivity C-reactive protein). A sample size of 176 patients (88 per arm) was determined to detect a significant reduction in infectious complications from 30% (control) to 12% (intervention), with 80% power and a two-sided α of 0.05. DISCUSSION: This study addresses a critical gap in evidence by focusing on nutritionally at-risk colorectal cancer patients. Unlike previous trials on unselected populations, this trial specifically evaluates the impact of immunonutrition in a high-risk group in which nutritional optimization may yield clinical benefits. Additionally, the multicenter design enhances generalizability. If preoperative immunonutrition effectively reduces postoperative complications, it could support a targeted nutritional intervention strategy for malnourished colorectal cancer patients, optimizing perioperative care and potentially reducing the healthcare burden. TRIAL REGISTRATION: Clinical Research Information Service KCT0008382. Registered on April 25, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lee SY, Kim CH, Ha GW, et al. Efficacy of preoperative immunonutrition in malnourished patients undergoing colorectal cancer surgery: a study protocol for a multicenter randomized clinical trial. Trials. 2025. PMID: 41024239. doi:10.1186/s13063-025-09082-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。